A clinical research consortium sponsored by NIAID
The Immune Tolerance Network is the product several years of planning by the National Institutes of Health and the extramural research community. We are grateful for the enormous effort and insight of our sponsors, who have brought this project to life and continue to support the mission of the Network.
The ITN is sponsored by the National Institute of Allergy and Infectious Diseases, with support from the Juvenile Diabetes Research Foundation. Additional funding has also been provided through the special type 1 diabetes appropriation overseen by the National Institute of Diabetes, Digestive and Kidney Diseases.
The NIAID provides the major support for scientists conducting research aimed at developing better ways to diagnose, treat and prevent the many infectious, immunologic and allergic diseases that afflict people worldwide. NIAID is composed of four extramural divisions: the Division of AIDS; the Division of Allergy, Immunology and Transplantation; the Division of Microbiology and Infectious Diseases; and the Division of Extramural Activities. In addition, NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville and Frederick, Maryland, and in Hamilton, Montana.
The Juvenile Diabetes Research Foundation (JDRF) is a not-for-profit, voluntary health agency with chapters and affiliates throughout the world. JDRF's main objective is to support and fund research to find a cure for diabetes and its complications. JDRF gives more money directly to diabetes research than any other private health agency in the world. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes.
JDRF also sponsors the ITN's Type 1 Diabetes Preclinical Consortium, an initiative to generate preclinical data to support combination therapy studies in type 1 diabetes. The consortium is a multi-center network of geographically diverse research laboratories that use standardized SOPs to enable data pooling and reproducibility across sites. The goal of the consortium is to generate high-quality, FDA-acceptable preclinical data to support attractice combination therapy approaches for type 1 diabetes.
